Literature DB >> 10084647

30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy.

K Hu1, B D Minsky, A M Cohen, D P Kelsen, J G Guillem, P P Paty, S H Quan.   

Abstract

BACKGROUND AND OBJECTIVES: There are a subset of patients with invasive anal cancers who undergo an excisional biopsy either before or after combined-modality therapy (CMT). The objective of this study is to determine whether these patients can be adequately treated with a lower dose of pelvic radiation therapy.
METHODS: A total of 25 patients were treated with CMT either before or after an excisional biopsy. The four subsets included 8 patients with initial excision followed by CMT with 30-34 Gy (EX/30), 6 patients with initial excision followed by CMT with 45-50.4 Gy (EX/45), 10 patients treated by CMT with 30 Gy followed by an excision (30/EX), and 1 patient by CMT with 45 Gy followed by an excision (45/EX).
RESULTS: For the total group, the actuarial 5-year disease-free survival was 78%, overall survival was 86%, colostomy-free survival was 91%, and local control was 82%. When patients received CMT either before or following an excision, the actuarial local control and survival results with 30-34 Gy vs. 45-50.4 Gy were similar. In contrast to radiation dose, in patients who received 30-34 Gy, the sequence of the excision (before or after CMT) did appear to have a borderline significant impact on local control. Actuarial 5-year local control was 100% for EX/30 vs. 67% for 30/EX (P = 0.08).
CONCLUSIONS: Because of the small number of patients in each group and the retrospective nature of the analysis, it is difficult to draw definitive conclusions from this study. However, our data suggest that in patients who are selected to undergo an initial excisional biopsy followed by CMT, 30 Gy may be an adequate radiation dose. Local control may be higher in patients who undergo an excisional biopsy followed by CMT compared with the converse.

Entities:  

Mesh:

Year:  1999        PMID: 10084647     DOI: 10.1002/(sici)1096-9098(199902)70:2<71::aid-jso2>3.0.co;2-y

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal.

Authors:  Thomas G Trautmann; James H Zuger
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

2.  Postoperative versus definitive chemoradiation in early-stage anal cancer. Results of a matched-pair analysis.

Authors:  B Berger; M Menzel; G Breucha; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-10       Impact factor: 3.621

3.  Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy.

Authors:  Michael Jones; George Hruby; Peter Stanwell; Sarah Gallagher; Karen Wong; Jameen Arm; Jarad Martin
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

Review 4.  Background and Current Treatment of Squamous Cell Carcinoma of the Anus.

Authors:  Rob Glynne-Jones; Waqar Saleem; Mark Harrison; Suzy Mawdsley; Marcia Hall
Journal:  Oncol Ther       Date:  2016-08-01

5.  Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).

Authors:  R Fish; C Sanders; N Ryan; S Van der Veer; A G Renehan; P R Williamson
Journal:  Colorectal Dis       Date:  2018-04-17       Impact factor: 3.788

6.  Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.

Authors:  A A Melcher; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

7.  Post-operative radiation therapy with or without chemotherapy for anal squamous cell carcinoma incidentally discovered after local excision: a propensity score matched analysis of retrospective multicenter study.

Authors:  Kyung Su Kim; Ah Ram Chang; Kyubo Kim; Hyeon Kang Koh; Won Il Jang; Hae Jin Park; Ji Hyun Chang; Mi-Sook Kim
Journal:  Br J Radiol       Date:  2019-12-17       Impact factor: 3.039

8.  The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.

Authors:  E de Winton; A G Heriot; M Ng; R J Hicks; A Hogg; A Milner; T Leong; M Fay; J MacKay; E Drummond; S Y Ngan
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.